Related Experiment Video
Updated: May 10, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Myocardial infarction after rituximab infusion
Dimitri Renard1, Luc Cornillet, Giovanni Castelnovo
1Department of Neurology, CHU Nîmes, Hôpital Caremeau, Place du Pr Debré, 30029 Nîmes Cedex 4, France. dimitrirenard@hotmail.com
Abstract:
Myocardial infarction after rituximab or other monoclonal antibody therapies has been reported in rare cases, all in patients with classical cardiovascular risk factors or associated inflammatory or lymphoproliferative disorders. We report the case of a 52-year-old man, without classical cardiovascular risk factors or associated inflammatory or lymphoproliferative disorder, treated for seronegative myasthenia with rituximab infusions complicated by myocardial infarction. The exact origin of myocardial infarction after monoclonal antibody treatment is unclear. Myocardial infarction is a rare but possibly fatal complication of rituximab infusion, even occurring in relatively young patients, without classical risk factors and without associated inflammatory or lymphoproliferative disorder.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease I: Introduction
Myocarditis IV: Nursing Management